The role of specific HDAC inhibitors, such as ACY1215, an HDAC6 inhibitor, further illustrates epidrugs’ therapeutic potential in ICI therapy for gynecological cancers with ARID1A mutations [197]. Here, HDAC9 is linked to female reproductive organ cancer.